Topic Archives: Biogen Idec (BIIB)

Alzheimer’s Disease is on everyone’s mind these days, thanks to Biogen’s (BIIB) controversial FDA approval for marketing Aduhelm as the first Alzheimer’s treatment in years, and arguably the first disease-modifying treatment at all… so both hope (for patients and families) and greed (for investors) are back in the picture. The dispute over the approval was […]

Everyone loves a good “this’ll cure Alzheimer’s!” story… both because we all know someone who has been touched by this awful disease, and because we know that a cure for Alzheimer’s would likely be a multi-billion-dollar drug. So the pundits tease early-stage hopefuls quite often, they fail almost all the time, and we keep hoping […]

I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]

Here’s the lead-in to the ad that caught our readers’ attention this week: “This ‘Perfect Storm’ Stock Is Set to Deliver Big Pharma a Swift and Devastating DEATHBLOW It Won’t Come Back From… “And Launch This Little Company on A 72-Hour, $8.98 Billion All-Out SPRINT” And there’s a deadline… today, in fact, when there will […]

Alzheimer’s Disease always gets a lot of attention from newsletter publishers, readers and investors — not only because we all know someone who suffers from this terrible malady, but because we know that the current treatments are ineffective and the market is huge… which means that any real solutions or more effective treatments could create […]

[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]

[Ed note: This article was originally published in June, 2013 when the shares of the stock teased, Alnylam (ALNY) were around $30 and the Oxford Club was saying that the first person to live to 1,000 is already alive … now they’re touting it as the holder of the “Magic” Keys to Immortality, but the […]

[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars!  You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]

Comments

  • I subscribed to Lashmet's letter three years ago. While I did not take all of his suggestions, I did invest in BIIB, IN...

  • In both SAVA and AVXL. Personal and financial reasons. Getting a lot of added interest today with BIIB approval....

  • Eisai is a partner with Biogen on aducanumab. ESALY is < $90 per share as opposed to BIIB at $285. ....

  • I'm afraid Deb109 could be correct in his statement, and you should look in one of these tickers; VIR OSUR TSE: 4528 ...

  • FYI, some more cautious perspectives On “repurposing” analysis to rescue the drug trial last year: https://www.s...

  • Check the timing of BIIB Mgt's bonus, stock options The cynic in me says they needed to hit a target level to cash in th...

  • Another failure in Alzheimer's Disease trials... BIIB and Eisai discontinued their late Phase 3 trials because they were...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info